SHARPE
Reported results
- Total revenue for the third quarter of 2026 increased 29% to $1.3 billion, compared to $1.0 billion for the third quarter of 2025.
- GAAP net income was $162 million for the third quarter of 2026, compared to a GAAP net loss of $(200) million for the third quarter of 2025.
- GAAP diluted earnings per share was $0.38 for the third quarter of 2026, compared to a loss per share of $(0.51) for the third quarter of 2025.
- Research and development expenses were $583 million for the third quarter of 2026, a 27% decrease compared to the third quarter of 2025.
- Cost of sales was $318 million for the third quarter of 2026, an increase of 54% compared to the third quarter of 2025.
- Cash, cash equivalents and investments as of September 30, 2026, were $8.0 billion, compared to $6.9 billion as of June 30, 2026.
Guidance
- Expected total revenue growth of 15% to 25% for full-year 2026.
- Cost of sales for 2026 is expected to be approximately $1.7 billion.
- Research and development expenses for 2026 are expected to be approximately $2.7 billion.
- Selling, general and administrative expenses for 2026 are expected to be approximately $1.0 billion.
- Capital expenditures for 2026 are expected to be approximately $0.2 billion.
- Year-end 2026 cash and investments are expected to be approximately $8.1 billion to $8.3 billion.
Price and volatility reaction
The stock moved +5.3% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 241.46 | 2026-11-05 |
| Close after release | 254.19 | 2026-11-06 |
| Realised move | +5.3% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.